Search
Ultragenyx Pharmaceutical Inc
RAREAdd to Watchlist
32.893USD
-0.497-1.49%
Market hours （ET）Quotes delayed by 15 min
3.23BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.49%
5 Days
+14.37%
1 Month
+37.40%
6 Months
+43.01%
Year to Date
+43.01%
1 Year
-9.53%
Key Figures
33.130Open
33.490High
332.56KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.34%Turnover Ratio
33.390Prev. Close
32.400Low
7.10MTurnover
LossP/E Static
-13.70P/B
0.00%Div Yield TTM
-46.70%ROA
42.37052wk High
0.39Volume Ratio
-569.18MNet Profit
98.30MShares
-6.1016EPS TTM
0.26Beta
-656.03%ROE
18.29052wk Low
3.26%Amplitude
77.94%Gross Margin
3.23BMarket Cap
15.25Reward/Risk
3.03%Risk Rate
TradingKey Stock Score of Ultragenyx Pharmaceutical Inc
Currency: USD Updated: 2026-06-30Key Insights
Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.94.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ultragenyx Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ultragenyx Pharmaceutical Inc Highlights
StrengthsRisks
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.98% year-on-year.
Fairly Valued
The company’s latest PE is -5.47, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 106.19M shares, decreasing 1.22% quarter-over-quarter.
Held by Frank Sands
Star Investor Frank Sands holds 2.88M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.82.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
50.944
Target Price
+66.05%
Upside Space
Ultragenyx Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ultragenyx Pharmaceutical Inc Info
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ticker SymbolRARE
CompanyUltragenyx Pharmaceutical Inc
CEOKakkis (Emil D)
Websitehttps://www.ultragenyx.com/
Related Instruments
-0.75%
-0.87%
-3.06%
-1.39%
-1.95%
-1.80%
+0.09%
+3.22%
-0.02%
+0.23%
+0.21%
-1.35%
-1.67%
-2.18%
+0.23%
0.00%
+0.40%
-2.07%
-0.69%
-0.37%Popular Instruments
52406.700
+210.400 (+0.40%)
29972.000
-252.600 (-0.84%)
7490.500
+8.100 (+0.11%)
15368.000
-227.000 (-1.46%)
70016.000
-840.000 (-1.19%)
6283.000
-44.000 (-0.69%)
68.748
-1.173 (-1.68%)
292.800
+3.440 (+1.19%)
196.000
-4.090 (-2.04%)
4099.830
+92.550 (+2.31%)
FAQs
What is the current price of Ultragenyx Pharmaceutical Inc (RARE)?
The current price of Ultragenyx Pharmaceutical Inc (RARE) is 33.39.
What is the symbol of Ultragenyx Pharmaceutical Inc?
The ticker symbol of Ultragenyx Pharmaceutical Inc is RARE.
What is the 52-week high of Ultragenyx Pharmaceutical Inc?
The 52-week high of Ultragenyx Pharmaceutical Inc is 42.37.
What is the 52-week low of Ultragenyx Pharmaceutical Inc?
The 52-week low of Ultragenyx Pharmaceutical Inc is 18.29.
What is the market capitalization of Ultragenyx Pharmaceutical Inc?
The market capitalization of Ultragenyx Pharmaceutical Inc is 3.29B.
Is Ultragenyx Pharmaceutical Inc (RARE) currently rated as Buy, Hold, or Sell?
According to analysts, Ultragenyx Pharmaceutical Inc (RARE) has an overall rating of Buy, with a price target of 50.94.
What is the Earnings Per Share (EPS TTM) of Ultragenyx Pharmaceutical Inc (RARE)?
The Earnings Per Share (EPS TTM) of Ultragenyx Pharmaceutical Inc (RARE) is -5.83.